Payment overview · 2025
General Payments
$176.17
10 reported records · 6 companies
Healthcare provider profile · identity verified
John Croker, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ORANGE CITY, FL · NPI 1518927763
Verified facts
What the public records show
CMS Open Payments records show John Croker, ARNP received $176.17 in general payments during 2025 across 10 reported records.
Lundbeck LLC accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $82.40 | 46.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.52 | 17.3% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.52 | 11.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.32 | 8.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $13.83 | 7.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.58 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.17 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $82.40 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 85 |
| Alprazolam | Alprazolam | 300 | 60 |
| Gabapentin | Gabapentin | 276 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 63 |
| Furosemide | Furosemide | 230 | 65 |
| Lisinopril | Lisinopril | 229 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 42 |
| Potassium Chloride | Potassium Chloride | 200 | 45 |
| Losartan Potassium | Losartan Potassium | 192 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 191 | 32 |
| Eliquis | Apixaban | 169 | 32 |
| Montelukast Sodium | Montelukast Sodium | 160 | 33 |
| Prednisone | Prednisone | 152 | 67 |
| Sertraline Hcl | Sertraline Hcl | 146 | 37 |
| Omeprazole | Omeprazole | 142 | 36 |
| Metformin Hcl | Metformin Hcl | 134 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 36 |
| Tramadol Hcl | Tramadol Hcl | 130 | 30 |
| Trazodone Hcl | Trazodone Hcl | 128 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 28 |
| Buspirone Hcl | Buspirone Hcl | 113 | 27 |
| Donepezil Hcl | Donepezil Hcl | 113 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 30 |
| Ibuprofen | Ibuprofen | 100 | 26 |
| Lidocaine | Lidocaine | 94 | 19 |
| Memantine Hcl | Memantine Hcl | 91 | 22 |
| Methenamine Hippurate | Methenamine Hippurate | 85 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 14 |
| Simvastatin | Simvastatin | 83 | 22 |
| Famotidine | Famotidine | 81 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 29 |
| Temazepam | Temazepam | 80 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 29 |
| Mirtazapine | Mirtazapine | 77 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 16 |
| Clonazepam | Clonazepam | 74 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 18 |
| Pregabalin | Pregabalin | 73 | 20 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 70 | 15 |
| Ondansetron Odt | Ondansetron | 68 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Carvedilol | Carvedilol | 67 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 11 |
| Levetiracetam | Levetiracetam | 63 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 11 |
| Sucralfate | Sucralfate | 61 | 16 |
| Azithromycin | Azithromycin | 60 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 17 |
| Celecoxib | Celecoxib | 56 | 13 |
| Divalproex Sodium | Divalproex Sodium | 56 | 12 |
| Spironolactone | Spironolactone | 56 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 16 |
| Linzess | Linaclotide | 54 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 16 |
| Mometasone Furoate | Mometasone Furoate | 51 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 11 |
| Risperidone | Risperidone | 49 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 15 |
| Promethazine Hcl | Promethazine Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 45 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 13 |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 37 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 33 |
| Alcohol Pads | Alcohol Antiseptic Pads | 39 | 11 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | 14 |
| Glipizide | Glipizide | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 13 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Ammonium Lactate | Ammonium Lactate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Scopolamine | Scopolamine | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Loxapine | Loxapine Succinate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.17 · 10 records | Lundbeck LLC | AIRSUPRA, CAPLYTA, Flexitouch Plus, Nimbl, REXULTI, SUBLOCADE, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error